Drugs / Latanoprost ophthalmic solution
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02981446 Comparator | Jan 2017 → Jan 2019 | open-angle glaucoma | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Latanoprost ophthalmic solution | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02981446 ↗ |
| Route | Other | “Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.” NCT02981446 ↗ |